DaVita Collaborates with Shanghai Hospital to Innovate Kidney Care Delivery in China

  DaVita Collaborates with Shanghai Hospital to Innovate Kidney Care Delivery
  in China

Business Wire

DENVER -- November 13, 2013

DaVita®, a division of DaVita HealthCare Partners Inc. (NYSE: DVA) and a
leading provider of kidney care services, today announced a collaboration in
the Yangpu District of Shanghai, China, with the aim of improving dialysis
patients’ quality of life while controlling or minimizing medical expenses.
With the support of the district government and approval of the health bureau,
DaVita and Shanghai Yangpu Antu Hospital are establishing a Renal Dialysis
Technology Collaboration Base at the 400-bed hospital.

Under the agreement, DaVita will provide consultation services to the public
hospital on advanced management processes for its renal outpatient visits and
dialysis treatments. Additionally, DaVita and the hospital will upgrade clinic
technology, expand the number of dialysis stations, and bring its
industry-leading quality of care and resulting clinical outcomes to the

“In support of Chinese health care reform, DaVita’s objective is to pilot a
sustainable, cost-effective and high-quality renal care and dialysis network
with Antu Hospital and within the Yangpu District,” said Atul Mathur,
president of DaVita’s Asia-Pacific operations. “We anticipate this
collaboration will serve as a model for other communities in China.”

The arrangement provides DaVita a platform for research aimed at improving
patient health outcomes and maximizing cost effectiveness for the Chinese
health care system.

“The end stage renal disease population in China is the ultimate beneficiary
of this collaboration,” said Dennis Kogod, DaVita’s chief operating officer.
“Not only does it promote health care quality improvement, safety and
therapeutic effectiveness, we believe it will minimize medical expenses and
lead to overall quality of life improvement for patients.”

Last year DaVita entered China with a joint venture deal with 3sBio Inc., a
leading Chinese biotechnology developer of biopharmaceutical products,
providing dialysis treatments in northeastern China.

DaVita and DaVita HealthCare Partners are trademarks or registered trademarks
of DaVita HealthCare Partners Inc. All other trademarks are the property of
their respective owners.

About DaVita

DaVita is the dialysis division of DaVita HealthCare Partners Inc., a Fortune
500® company that, through its operating divisions, provides a variety of
health care services to patient populations throughout the United States and
abroad. A leading provider of kidney care in the United States, DaVita
delivers dialysis services to patients with chronic kidney failure and end
stage renal disease. DaVita strives to improve patients’ quality of life by
innovating clinical care, and by offering integrated treatment plans,
personalized care teams and convenient health-management services. As of
September 30, 2013, DaVita operated or provided administrative services at
2,042 outpatient dialysis centers located in the United States serving
approximately 166,000 patients. The company also operated 66 outpatient
dialysis centers located in ten countries outside the United States. DaVita
supports numerous programs dedicated to creating positive, sustainable change
in communities around the world. The company’s leadership development
initiatives and social responsibility efforts have been recognized by Fortune,
Modern Healthcare, Newsweek and WorldBlu. For more information, please visit

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the
federal securities laws, including statements related to anticipated and
prospective growth of certain of our international ventures and the clinical
outcomes that they will deliver. Factors which could impact future results
include the risks and uncertainties associated with expansion of our
operations and services to markets outside the United States, including local
governmental regulations, general economic and other market conditions,
competition, and the other applicable risk factors set forth in our SEC
filings, including our Annual Report on Form 10-K for the year ended December
31, 2012, and subsequent quarterly reports filed on Form 10-Q. The
forward-looking statements should be considered in light of these risks and
uncertainties. We base our forward-looking statements on information currently
available to us at the time of this release, and we undertake no obligation to
update or revise any forward-looking statements, whether as a result of
changes in underlying factors, new information, future events or otherwise.


David Tauchen, 303-876-2802
Press spacebar to pause and continue. Press esc to stop.